Response to emicizumab
| Response to emicizumab . | Median . | IQR . | Range . |
|---|---|---|---|
| Bleeding stopped, d | 3 | 3-4 | 2-15* |
| Day last rhFVIIa injection | 1.5 | 0.8-4 | 0-16* |
| FVIII (chromogenic), d | |||
| >5% (human) | 4 | 3.3-4.8 | 1-13 |
| >10% (human) | 11 | 7.5-12 | 5-13 |
| >50% (human) | 105 | 33-184 | 9-270 |
| >5% (bovine) | 60 | 26-73 | 12-201 |
| >10% (bovine) | 85 | 33-112 | 12-270 |
| >50% (bovine) | 115 | 67-185 | 18-403 |
| Response to emicizumab . | Median . | IQR . | Range . |
|---|---|---|---|
| Bleeding stopped, d | 3 | 3-4 | 2-15* |
| Day last rhFVIIa injection | 1.5 | 0.8-4 | 0-16* |
| FVIII (chromogenic), d | |||
| >5% (human) | 4 | 3.3-4.8 | 1-13 |
| >10% (human) | 11 | 7.5-12 | 5-13 |
| >50% (human) | 105 | 33-184 | 9-270 |
| >5% (bovine) | 60 | 26-73 | 12-201 |
| >10% (bovine) | 85 | 33-112 | 12-270 |
| >50% (bovine) | 115 | 67-185 | 18-403 |
Medians, IQR, range; n = 12.
One patient with an abdominal wound requiring repetitive single doses of rhFVIIa for surgical procedures.